March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings’ (LNTH.O) prostate cancer imaging agent, aimed at improving scanning access through increased production capacity.
Shares of the company were up about 3% in extended trading.
The imaging agent, Pylarify, targets prostate-specific membrane antigen (PSMA), a protein that is commonly elevated in prostate cancer cells and used to detect metastatic or recurrent disease in patients.
The new formulation is designed to optimize the manufacturing process and is expected to increase the batch size by about 50%, while also improving margins for the company.

SBIO

Reuters

iShares US Pharma

Health Care Select Sector SPDR

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Lantheus

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

Ark Genomic Revolution ETF

US FDA approves Lantheus' new prostate cancer imaging formulation